Advice
In the absence of a submission from the holder of the marketing authorisation
bevacizumab (Avastin) in addition to platinum-based chemotherapy, is not recommended for first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- bevacizumab (Avastin)
- SMC ID:
- 425/07
- Indication:
- non-small cell lung cancer
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 December 2007